This article refers to:
In the article “Selective Raf inhibition in cancer therapy”, published in the December 2007 issue of Expert Opinion on Therapeutic Targets (Expert Opin Ther Targets 2007;11(12):1587-1609) there is a structure in Figure 4 that is identified as PLX4032, a proprietary compound of Plexxikon. Plexxikon have identified this structure as being incorrect and would like to clarify this. The structure of PLX4032 has not been disclosed.
Informa Healthcare would like to apologise for any confusion caused.